<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03356158</url>
  </required_header>
  <id_info>
    <org_study_id>CPGJ602-001</org_study_id>
    <nct_id>NCT03356158</nct_id>
  </id_info>
  <brief_title>A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase 1 Study of Recombinant Anti-Epidermal Growth Factor Receptor (EGFR) Human-mouse Chimeric Monoclonal Antibody Injection in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, parallel designed study to assess the pharmacokinetics, safety and&#xD;
      tolerability of the single-dose and multi-dose of a recombinant anti-EGFR monoclonal antibody&#xD;
      (CPGJ602) in patients with at least one prior chemical regimen failed metastatic colorectal&#xD;
      cancer. The immunogenicity and preliminary efficacy of CPGJ602 will also be assessed. The&#xD;
      study includes 3 parts: part 1: after a single dose of CPGJ602 or cetuximab (the active&#xD;
      comparator), the patients will be observed for 4 weeks; part 2: CPGJ602 or cetuximab will be&#xD;
      administered to the patients once a week for 5 weeks; part 3: CPGJ602 will be administered to&#xD;
      the patients once a week until the patient's death or the withdrawal decision of the patient&#xD;
      and/or investigator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      To assess the pharmacokinetics, safety and tolerability of the single-dose and multi-dose of&#xD;
      CPGJ602 administered by intravenous infusion.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      To assess the immunogenicity and anti-tumor activity of CPGJ602, compare the pharmacokinetics&#xD;
      and immunogenicity between CPGJ602 and the active comparator, cetuximab, and to provide&#xD;
      scientific basis for the subsequent phase 2/3 clinical trials.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      This is an open-label, parallel designed study in patients with at least one prior chemical&#xD;
      regimen failed metastatic colorectal cancer. The study can be divided into 3 parts:&#xD;
&#xD;
      Part 1: Single-dose Part&#xD;
&#xD;
        -  Arm A: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;&#xD;
&#xD;
        -  Arm B: CPGJ602, IV over 2 hours, 400 mg/m2 X 1;&#xD;
&#xD;
        -  Arm C: Cetuximab, IV over 2 hours, 400 mg/m2 X 1.&#xD;
&#xD;
      Part 2: Multi-dose Part&#xD;
&#xD;
      The subjects from arm A in Part 1 will be randomized into arm B or C.&#xD;
&#xD;
        -  Arm B: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1&#xD;
           hour for each time;&#xD;
&#xD;
        -  Arm C: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1&#xD;
           hour for each time. The completion of Day 63 Visit (the visit on the 7th day after the&#xD;
           5th dose in Part 2) can be considered as the completion of the study.&#xD;
&#xD;
      Part 3 (Follow-up Part)&#xD;
&#xD;
      CPGJ602, IV over 1 hour, QW, 250mg/m2, until the patient's death or the withdrawal decision&#xD;
      of the patient and/or investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Day 0 - Day 21 for single dose and Day 28 - Day 63 for multiple doses</time_frame>
    <description>part 1 for single dose and part 2 for multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life of CPGJ602 in blood [t1/2]</measure>
    <time_frame>Day 0 - Day 21 for single dose and Day 28 - Day 63 for multiple doses</time_frame>
    <description>part 1 for single dose and part 2 for multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>Day 0 - Day 21 for single dose and Day 28 - Day 63 for multiple doses</time_frame>
    <description>part 1 for single dose and part 2 for multiple doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events [AEs]</measure>
    <time_frame>Day -28 to 1 month following the last administration</time_frame>
    <description>to evaluate the safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody [ADA]</measure>
    <time_frame>Day 0 to Day 63, and in the follow-up period.</time_frame>
    <description>to evaluate the Immunogenicity; if the result is positive, Neutralizing Antibody [NAB] will also be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate [ORR]</measure>
    <time_frame>Day -28 - Day 63</time_frame>
    <description>the rate of completely response [CR] and partial response [PR] patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carcinoembryonic antigen [CEA]</measure>
    <time_frame>Day -28 - Day 63</time_frame>
    <description>Tumor Marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer antigen [CA19-9]</measure>
    <time_frame>Day -28 - Day 63</time_frame>
    <description>Tumor Marker</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CPGJ 602 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPGJ 602 normal dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab normal dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CPGJ602</intervention_name>
    <description>Injection, q.w., 20 mg: 100 ml</description>
    <arm_group_label>CPGJ 602 low dose</arm_group_label>
    <arm_group_label>CPGJ 602 normal dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Injection, q.w., 20 mg: 100 ml</description>
    <arm_group_label>Cetuximab normal dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-70 years old, male or female.&#xD;
&#xD;
          2. Histologically or cytologically confirmed metastatic CRC, and have failed (disease&#xD;
             progression or intolerance) at least one prior chemical regimen containing&#xD;
             oxaliplatin, irinotecan or 5-FU, etc.&#xD;
&#xD;
          3. ECOG performance status 0 or 1.&#xD;
&#xD;
          4. Estimated life expectancy ≥ 3 months.&#xD;
&#xD;
          5. RAS (including K-ras and N-ras) wide type status.&#xD;
&#xD;
          6. Adequate bone marrow, hepatic and renal functions. Hematopoietic:&#xD;
&#xD;
             Leukocytes (WBC)&gt;4.0×109/L or Absolute Neutrophil Count (ANC)&gt; 1.5×109/L, Platelet&#xD;
             Count (PLT)&gt;80×109/L, Hemoglobin (Hb)&gt;90g/ L; Hepatic: Total Bilirubin (T-Bil)≤1.5×ULT&#xD;
             (Upper Limit of Normal), Alanine Transaminase (ALT)/ Aspartate Transaminase&#xD;
             (AST)≤2.5×ULT or ≤5×ULT in case of liver metastases; Renal: Blood Urea Nitrogen&#xD;
             (BUN)≤1.5×ULT, Serum Creatinine (Cr) ≤ 1.5×ULT.&#xD;
&#xD;
          7. At least one measurable disease based on RECIST criteria (v 1.1).&#xD;
&#xD;
          8. Signed informed consent on a voluntary basis at screening, and no geographical&#xD;
             condition that would preclude the study compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Less than 28 days since prior chemotherapy, radiotherapy or surgery (diagnosis biopsy&#xD;
             is allowed).&#xD;
&#xD;
          2. Previous epidermal growth factor receptor (EGFR) targeted therapies (including&#xD;
             monoclonal antibody, tyrosine kinase inhibitor [TKI] and other EGFR targeted&#xD;
             therapies, such as cetuximab, nimotuzumab, panitumumab, gefitinib, erlotinib, and&#xD;
             icotinib, etc.&#xD;
&#xD;
          3. Known hypersensitivity to study drugs or any of the excipients.&#xD;
&#xD;
          4. Known or clinical suspected brain metastases and/or disease of meninges.&#xD;
&#xD;
          5. Clinically significant cardiovascular or cerebrovascular dis ease, history of&#xD;
             myocardial infarction (MI) in the latest 6 months, or high-risk of uncontrolled&#xD;
             cardiac arrhythmias.&#xD;
&#xD;
          6. History of acute or sub-acute intestinal obstruction, or of inflammatory bowel&#xD;
             disease.&#xD;
&#xD;
          7. A serious and uncontrolled concomitant disease which, in the investigator's opinion,&#xD;
             rules out the patient's participation in the study, such as history of malignancies&#xD;
             other than CRC (with the exception of: curatively treated carcinoma of the skin&#xD;
             [except for melanoma]; cured cervical cancer or basal cell skin cancer, ductal&#xD;
             carcinoma in situ [DICS], endometrial carcinoma [stage I grade 1]; and other solid&#xD;
             tumors including lymphoma without bone marrow infiltration for which the patient has&#xD;
             been disease-free for 5 years), uncontrolled hypertension, diabetes mellitus (DM),&#xD;
             peripheral neuropathy, and infectious diseases (including viral, bacterial and&#xD;
             parasitic infections), etc.&#xD;
&#xD;
          8. Pregnancy or lactation, or a fertility plan during the participation in this study.&#xD;
&#xD;
          9. No more than 4 weeks or no more than 5 times of t1/2 since prior investigational&#xD;
             agents.&#xD;
&#xD;
         10. Other situations that impede the patient's participation in the study at the&#xD;
             discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianming Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>the Afflicated Hospital of Academy of Military Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quanrui Wu, Master</last_name>
    <phone>13601126093</phone>
    <email>wuquanrui@3sbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan, Doctor</last_name>
      <phone>0571-86006922</phone>
      <email>shonco@sina.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer,</keyword>
  <keyword>Recombinant Anti-EGFR Monoclonal Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

